Has Mercy Stanley received payments from drug or device companies?

Yes. Drug and device makers reported $3,681 in general payments to Mercy Stanley across 119 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Mercy Stanley did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Mercy Stanley come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Mercy Stanley

Family · Houston, TXNPI 1548511603

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $3,096 of the $3,681 with a category attached, or 84.1%. 24 manufacturers reported payments, led by Astellas Pharma US Inc at 29.5% of the total. 2025 is the largest year on record at $1,294, more than ten times the $67 reported in 2021. Among family clinicians in TX with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$3,681in general payments, 2019–2025

Across 119 payments — averaging $30.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Astellas Pharma US Inc$1K
Incyte Corporation$323
Lilly USA, LLC$311
AstraZeneca$260
Sobi, Inc$196
Daiichi Sankyo Inc.$196
plus $1K from 18 others

What the payments were for

Food & beverage$3,09684%
Education$58616%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Astellas Pharma US Inc	24	$1,085
Incyte Corporation	12	$323
Lilly USA, LLC	12	$311
AstraZeneca	9	$260
Sobi, Inc	4	$196
Daiichi Sankyo Inc.	7	$196
Syndax Pharmaceuticals, Inc.	6	$195
Bristol Myers Squibb	7	$134
Beigene USA, Inc.	7	$132
AbbVie	5	$131
Pharmaessentia USA Corporation	4	$116
Novartis	4	$107
Servier Pharmaceuticals LLC	3	$74
Rigel Pharmaceuticals, Inc.	2	$63
Pfizer	2	$58
Amgen	2	$54
Johnson & Johnson	2	$53
Taiho Oncology, Inc.	1	$34
Blueprint Medicines Corporation	1	$32
GSK	1	$30
Merck	1	$28
Takeda Pharmaceuticals U.S.A., Inc.	1	$27
Pharmacyclics LLC, An Abbvie Company	1	$24
Adaptive Biotechnologies Corporation	1	$18

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

XOSPATA$140

How this compares

$3,681 in reported general payments places this provider in the 90th percentile of 15,456 family providers in Texas.

See all family providers in Texas →

Other family in Houston

Robin BeachHouston$428K
Sarah AguilarHouston$199K
Margaret WhiteHouston$85K
Cheryl HaseebHouston$42K
Kendrick ClackHouston$28K
David WeirDallas$959K
April LopezMcAllen$417K
Sie ThomasDallas$197K
Anna CastroSan Antonio$184K
Jill CampbellShenandoah$182K

See the full list for Texas →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →